Kalaris Therapeutics, Inc.

Contributing Author

Recent Articles by Kalaris Therapeutics, Inc.

5 hours	Kalaris to Present at Clinical Trials at the Summit 2026 KLRS GlobeNewswire
May-12	Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates KLRS GlobeNewswire
Jan-28	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting KLRS GlobeNewswire
Dec-17	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement KLRS +20.32% GlobeNewswire
Dec-17	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD KLRS +20.32% GlobeNewswire
Nov-12	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates KLRS GlobeNewswire
Nov-03	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer KLRS GlobeNewswire
Oct-30	Kalaris to Present at Stifel 2025 Annual Healthcare Conference KLRS GlobeNewswire
Sep-15	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS +35.04% KLRS GlobeNewswire
Sep-15	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS GlobeNewswire
Aug-13	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates KLRS -8.43% GlobeNewswire
Jun-02	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference KLRS GlobeNewswire
May-23	Kalaris to Participate at Stifel Ophthalmology Forum KLRS GlobeNewswire
May-14	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights KLRS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)